Tuesday, June 30, 2026

Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs

›
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmace...
Monday, June 29, 2026

Elevar Therapeutics Announces FDA Acceptance for Review of New Drug Application for Lirafugratinib as Second-line Cholangiocarcinoma Treatment

›
Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevat...
Saturday, June 27, 2026

How statins harm muscles—and how to stop it

›
In continuation of my update  on statin   Statins have transformed heart health, saving millions of lives by lowering cholesterol and reduci...
Thursday, June 25, 2026

Methamphetamine impairs dopamine uptake by targeting a protein modification

›
In continuation of my update on  Methamphetamine Dopamine brings on a surge of pleasure, but too much dopamine in a synapse can ultimately l...
Tuesday, June 23, 2026

Polyphenol-rich diets associated with lower long-term cardiovascular disease risk

›
In continuation of my update on  Polyphenol-rich diets  People who regularly consume polyphenol-rich foods and drinks, such as tea, coffee, ...
Wednesday, June 17, 2026

Polyphenol-rich diets associated with lower long-term cardiovascular disease risk

›
People who regularly consume polyphenol-rich foods and drinks, such as tea, coffee, berries, cocoa, nuts, whole grains and olive oil, may ha...
Tuesday, June 16, 2026

Lilly's announces results from Phase III clinical trial of Jaypirca

›
In continuation of my update on  pirtobrutinib Eli Lilly and Company announced results from the Phase 3 BRUIN CLL-322 clinical trial of Jayp...

Alternative sweetener sorbitol linked to liver disease

›
Sweeteners such as aspartame, found in Equal packets, sucralose (Splenda), or sugar alcohols are often seen as healthier alternatives to foo...
Monday, June 15, 2026

Drug developed for inherited bleeding disorder shows promising trial results

›
Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting one in 3,800 persons....
Saturday, June 13, 2026

Eylea HD (aflibercept) Approved by FDA for the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing Across Approved Indications

›
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food and Drug Administration (FDA) approval of Eylea HD (aflibercept) Inje...
Thursday, June 11, 2026

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

›
Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering therapies that target the root causes of inflammation-driven...
Monday, June 8, 2026

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

›
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of two pivotal, s...
Saturday, June 6, 2026

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma

›
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) ...
Friday, June 5, 2026

Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL

›
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), t...
Thursday, June 4, 2026

FDA Grants Orphan Drug Designation for Tinostamustine in Malignant Glioma

›
Purdue Pharma L.P. (“Purdue”) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to ...